奥曲肽所致低血糖风险的回顾性研究  

A retrospective study on the risk factors for hypoglycemia caused by octreotide

作　　者：王娜[1] 王海涛[1] 杨鑫[1] 毛文彬 张莉[1] 张抗怀[1] WANG Na;WANG Hai-tao;YANG Xin;MAO Wen-bin;ZHANG Li;ZHANG Kang-huai(Department of Pharmacy,the Second Affiliated Hospital,Xi′an Jiaotong University,Xi′an 710004,China;Outpatient Service Office,the Second Affiliated Hospital,Xi′an Jiaotong University,Xi′an 710004,China)

机构地区：[1]西安交通大学第二附属医院药学部,陕西西安710004 [2]西安交通大学第二附属医院门诊办,陕西西安710004

出　　处：《实用药物与临床》2021年第1期82-84,共3页Practical Pharmacy and Clinical Remedies

摘　　要：目的探讨奥曲肽引起低血糖风险的危险因素,为临床安全用药提供参考。方法回顾性分析476例接受奥曲肽治疗的患者的临床资料,对奥曲肽治疗中并发低血糖的相关危险因素进行二元Logistic回归分析。结果奥曲肽治疗中并发低血糖的发生率为6.51%,发生低血糖组的患者年龄高于未发生组[(62.81±13.65)岁vs.(56.50±15.14)岁,P=0.02],奥曲肽的日剂量高于未发生组[(0.73±0.26)mg/d vs.(0.53±0.30)mg/d,P<0.01]。二元Logistic回归分析表明,奥曲肽治疗并发低血糖的危险因素包括年龄(OR=3.95,95%CI:1.78~8.79,P=0.03)、奥曲肽的日剂量(OR=4.13,95%CI:1.95~8.74,P<0.01)、合并糖尿病(OR=2.94,95%CI:1.32~6.53,P<0.01)及使用胰岛素(OR=2.93,95%CI:1.40~6.11,P<0.01)。结论临床使用奥曲肽的过程中应监测患者的血糖水平,尤其针对年龄高于60岁、奥曲肽日剂量大于0.7 mg/d、合并糖尿病及使用胰岛素的患者,应警惕低血糖的发生。Objective To investigate the risk factors for hypoglycemia caused by octreotide,and to provide reference for clinical safe medication.Methods The clinical data of 476 patients who received octreotide therapy were collected and analyzed retrospectively.The risk factors associated with hypoglycemia induced by octreotide were identified via Binary Logistic regression analysis.Results The incidence of hypoglycemia induced by octreotide was 6.51%.Patients with hypoglycemia were older[(62.81±13.65)years vs.(56.50±15.14)years,P=0.02],and took higher daily dose of octreotide[(0.73±0.26)mg/d vs.(0.53±0.30)mg/d,P<0.01].Binary Logistic regression analysis showed that the risk factors associated with hypoglycemia induced by octreotide were age(OR=3.95,95%CI:1.78~8.79,P=0.03),the daily dose of octreotide(OR=4.13,95%CI:1.95~8.74,P<0.01),combined diabetes(OR=2.94,95%CI:1.32~6.53,P<0.01)and using insulin(OR=2.93,95%CI:1.40~6.11,P<0.01).Conclusion The blood glucose level of patients should be monitored when octreotide is used in clinical therapy.The patients should be closely monitored for hypoglycemia especially when the age is over 60,the daily dose of octreotide is more than 0.7 mg,or patients are with diabetes or using insulin.

关 键 词：奥曲肽 低血糖 危险因素 

分 类 号：R969[医药卫生—药理学]